Anti-angiogenic properties of calcium trifluoroacetate

被引:2
|
作者
Bussolati, Benedetta [2 ]
Ribatti, Domenico [3 ]
Munaron, Luca [4 ]
Bartorelli, Alberto [5 ]
Bussolati, Gianni [1 ]
机构
[1] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy
[2] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, I-10126 Turin, Italy
[3] Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy
[4] Univ Turin, Ctr Complex Syst Mol Biol & Med SyBioM, Nanostruct Interfaces & Surfaces Ctr Excellence N, Dept Anim & Human Biol, I-10126 Turin, Italy
[5] Univ Milan, I-20122 Milan, Italy
关键词
Angiogenesis; Calcium; Trifluoroacetate; NITRIC-OXIDE PRODUCTION; CHORIOALLANTOIC MEMBRANE; INTRACELLULAR CALCIUM; MECHANISMS; VEGF; PROLIFERATION;
D O I
10.1016/j.mvr.2009.07.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Endothelial cell proliferation and the formation of new vessels are strictly regulated by angiogenic factors (e.g., VEGF) that induce the activation of signal transduction pathways controlled by calcium dynamics. Using in vitro and in vivo experiments, we investigated the effect of calcium trifluoroacetate (CaTFAc), a complex, poorly dissociated salt that is characterized by its low toxicity, on angiogenesis. In vitro, CaTFAc inhibited VEGF-induced effects on endothelial cell proliferation. In two in vivo models of angiogenesis, a Matrigel plug in mice and a chick embryo chorioallantoic membrane, CaTFAc inhibited the VEGF-induced formation of new vessels. The exact mechanism of action is still under investigation, but in vitro experiments demonstrate that CaTFAc induced a reversible increase in the levels of intracellular calcium under basal conditions and prevented calcium signaling induced by VEGF. These results are the first to suggest that CaTFAc may be useful for the treatment of diseases caused by enhanced angiogenesis. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 50 条
  • [1] Anti-angiogenic properties of plaunotol
    Kawai, K
    Tsuno, NH
    Kitayama, J
    Okaji, Y
    Yazawa, K
    Asakage, M
    Yamashita, H
    Watanabe, T
    Takahashi, K
    Nagawa, H
    ANTI-CANCER DRUGS, 2005, 16 (04) : 401 - 407
  • [2] Anti-angiogenic properties of temozolomide
    Kurzen, H
    Schmitt, S
    Möhler, T
    Näher, H
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (03) : 812 - 812
  • [3] Anti-angiogenic properties of opticin
    Sutton, Matthew John
    le Goff, Magali
    West, David
    Bishop, Paul
    Slevin, Mark
    FASEB JOURNAL, 2007, 21 (05): : A528 - A528
  • [4] Anti-angiogenic properties of artemisinin derivatives
    Wei, Tianshu
    Liu, Ju
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 (04) : 972 - 978
  • [5] Insights into the anti-angiogenic properties of phosphaplatins
    Yang, Lu
    Moghaddas, Shadi
    Dezvareh, Homa
    Belkacemi, Louiza
    Bark, Steven J.
    Bose, Rathindra N.
    Do, Loi H.
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2016, 164 : 5 - 16
  • [6] Anti-angiogenic properties of a sulindac analogue
    Pyriochou, A.
    Tsigkos, S.
    Vassilakopoulos, T.
    Cottin, T.
    Zhou, Z.
    Gourzoulidou, E.
    Roussos, C.
    Waldmann, H.
    Giannis, A.
    Papapetropoulos, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (08) : 1207 - 1214
  • [7] A is for anti-angiogenic
    不详
    NATURE MEDICINE, 2001, 7 (04) : 418 - 418
  • [8] ANTI-ANGIOGENIC ISOFORMS OF VEGF - A KEY TO ANTI-ANGIOGENIC THERAPY
    Bates, D. O.
    Harper, S. J.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3207 - 3208
  • [9] Anti-angiogenic properties of PM060184
    Galmarini, Carlos M.
    Guillen, Maria J.
    Martinez-Leal, Juan F.
    Martinez-Diez, Marta
    Aviles, Pablo
    CANCER RESEARCH, 2016, 76
  • [10] The anti-angiogenic properties of the ocular glycoprotein opticin
    Bishop, P
    Slevin, M
    West, D
    Valdramidou, D
    Humphries, M
    Le Goff, M
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2006, 87 (01) : A45 - A45